Project description:The immune system is crucial in regulating colorectal cancer tumorigenesis. Identification of immune-related transcriptomic signatures derived from the peripheral blood of colorectal cancer patients will provide insights into colorectal cancer pathogenesis and suggest novel clues to potential colorectal cancer immunotherapy strategies. We used microarrays to detail the blood-based gene expression of colorectal cancer patients and healthy controls to identify the colorectal cancer-specific immune genes potentially diagnostic for colorectal cancer.
Project description:In this work, we performed gene expression profiling for twenty-paired blood samples collected from healthy controls before and after colonoscopy, and twenty blood samples collected from<br>colorectal cancer patients after colonoscopy. The aim of this study is to determine how significant the colonoscopy procedure may impact the global gene expression in human peripheral blood, and whether this colonoscopy induced variability would bias the biomarker research for colorectal cancer early detection.
Project description:Colorectal cancer is the third most common malignancy and the fourth most common cause of cancer mortality worldwide. In 2008, more than one million cases were newly diagnosed, and more than 600,000 people died from the disease. Given its slow development from removable precancerous lesions and curable early stages, screening for CRC has the potential to reduce both the incidence and mortality of the disease. However, compliance with current screening methods remains poor and there is a clear need for an accurate in vitro blood test to increase participation in colorectal cancer screening. In this study, we performed genome-wide gene expression profiling of peripheral blood samples from 100 healthy controls and 100 colorectal cancer patients using PAXgeneTM technology and Affymetrix GeneChip® microarrays. We show that monitoring gene expression in blood results in distinct transcriptional profiles between the controls and cancer patients. Thus, the microarray-based blood gene expression profiling holds great promise for developing novel biomarkers for colorectal cancer detection.
Project description:The study profiles genome-wide miRNA expression in blood from 15 early-onset SZ (EOS) cases and 15 healthy controls. A total of 1070 miRNAs were detected by the microarrays in our samples. We profiles miRNA expression in 15 schizophrenia samples and 15 healthy controls to explore the alteration of miRNAs in schizophrenia.
Project description:The study profiles genome-wide mRNA expression in blood from 18 early-onset SZ (EOS) cases and 12 healthy controls. A total of 1070 mRNAs were detected by the microarrays in our samples. 18 schizophrenia samples and 12 healthy controls were used to acquire blood expression profiles
Project description:The study profiles genome-wide mRNA expression in blood from 18 early-onset SZ (EOS) cases and 12 healthy controls. A total of 1070 mRNAs were detected by the microarrays in our samples.
Project description:MicroRNAs (miRNAs) are intrinsic regulators in the various cellular processes, and their abnormalities are considered to be involved in the onset of human disorders, including cancer. Circulating miRNA is focused as new cancer biomarker however it is regarded that circulating RNA are released not only from tumor but also by various pathways. Recently, exosomes, small membrane vesicles, have been a major interest in cancer research field, because of their unique biological properties. Exosomes are secreted from various cells and the components (Lipids, mRNAs, miRNAs and proteins) reflect origin of the cells secreting them. Identification of exosomal miRNAs from cancer cells is expected to provide useful biomarkers of cancer. To identify specific exosomal miRNAs as candidate biomarkers for colorectal cancer, we profiled exosomal miRNAs in sera of colon cancer patients (n=88) at various TNM stages (I to IV) and healthy controls (n=11) and selected significantly higher microRNAs in serum exosomes of colorectal cancer patients than that of healthy controls. Moreover, we tried to detect their serum exosome levels of using samples from patients after surgical resection of primary tumors (n=24).